白蛋白替代治疗脓毒性休克的多中心随机对照试验(ARISS)方案
ARISS 研究为多中心随机对照试验,拟纳入成人脓毒性休克患者,比较白蛋白替代并维持血清白蛋白至少 30 g/l 与常规晶体液复苏对 90 天死亡率的影响;计划分析 1412 例,按 15% 脱落率需分配 1662 例。
要点
- 成人脓毒性休克发病 24 小时内随机分组,治疗组给予 60 g 人血白蛋白 20% 负荷剂量。
- 治疗组在 ICU 内维持血清白蛋白至少 30 g/l,最长 28 天,使用 40–80 g 人血白蛋白 20% 输注。
- 主要终点为 90 天死亡率,计划分析 1412 例(每组 706 例)。
核心结论
- 该试验旨在验证白蛋白替代并维持血清白蛋白至少 30 g/l 能否改善脓毒性休克患者的生存。
研究设计与样本
- 多中心随机对照试验,成人(≥18 岁)脓毒性休克患者在发病最长 24 小时内随机分配至治疗组或对照组。
- 计划分析 1412 例,每组 706 例;按 15% 脱落率,需分配 1662 例。
- 样本量估算假设 90 天死亡率相对降低 15%,即绝对降低 7.5 个百分点至 42.5%(相对风险 1.18)。
关键数值与推荐
- 治疗组给予 60 g 人血白蛋白 20% 负荷剂量,输注 2–3 小时。
- 治疗组在 ICU 内维持血清白蛋白至少 30 g/l,最长 28 天,使用 40–80 g 人血白蛋白 20% 输注。
- 对照组按常规实践,以晶体液作为脓毒性休克复苏和维持阶段的首选。
- 主要终点为 90 天死亡率;次要终点包括 28 天、60 天、ICU 和住院死亡率、器官功能障碍/衰竭、ICU 总输液量和总液体平衡、ICU 和住院时间。
临床怎么用
- 该方案为脓毒性休克白蛋白替代治疗提供了明确的给药策略和血清白蛋白目标值,结果可能影响临床治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Albumin is a key regulator of fluid distribution within the extracellular space and has several properties beyond its oncotic activity. The accumulating evidence suggests that supplementation of albumin may provide survival advantages only when the insult is severe as in patients with septic shock. METHODS/DESIGN: The randomized controlled multicentre study of albumin replacement therapy in septic shock (ARISS) investigates whether the replacement with albumin and the maintenance of its serum levels of at least 30 g/l for 28 days improve survival in patients with septic shock compared to resuscitation and volume maintenance without albumin. Adult patients (≥ 18 years) with septic shock are randomly assigned within a maximum of 24 h after the onset of septic shock after obtaining informed consents to treatment or control groups. Patients assigned to the treatment group receive a 60-g loading dose of human albumin 20% over 2-3 h. Serum albumin levels are maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion. The control group is treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock. The primary endpoint is 90 days mortality and secondary endpoints include 28-day, 60-day, ICU, and in-hospital mortality, organ dysfunction/failure, total amount of fluid administration and total fluid balance in the ICU, and lengths of ICU and hospital stay. In total, 1412 patients need to be analysed, 706 per group. For the sample size estimation, a 15% reduction in 90-day mortality is assumed, i.e. an absolute reduction of 7.5% points to 42.5% (relative risk 1.18). Assuming a dropout rate of 15%, a total of 1662 patients need to be allocated. DISCUSSION: The results of the clinical trial may influence the treatment of patients with septic shock. The expected improvement in patient survival may result in a reduction in the resources currently used in the treatment of these patients and in the socioeconomic burden of this disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT03869385 . Registration on 18 July 2019. Protocol version: Final 3.0.
引用
- Sakr Y, Bauer M, Nierhaus A, et al. Randomized controlled multicentre study of albumin replacement therapy in septic shock (ARISS): protocol for a randomized controlled trial. Trials. 2020. PMID: 33287911. doi:10.1186/s13063-020-04921-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。